Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein

Nature Communications

Volumn 8, Issue , 2017, Pages

  Tang, Maoxue ^a   Gao, Guangping ^b   Rueda, Carlos B ^a   Yu, Hang ^c   Thibodeaux, David N ^c   Awano, Tomoyuki ^a   Engelstad, Kristin M ^a   Sanchez Quintero, Maria Jose ^a   Yang, Hong ^a   Li, Fanghua ^a   Li, Huapeng ^b   Su, Qin ^b   Shetler, Kara E ^a   Jones, Lynne ^d   Seo, Ryan ^e   McConathy, Jonathan ^f   Hillman, Elizabeth M ^c   Noebels, Jeffrey L ^e   De Vivo, Darryl C ^a   Monani, Umrao R ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; GLUCOSE; GLUCOSE TRANSPORTER;

BRAIN; GENE EXPRESSION; GLUCOSE; MUTAGENICITY; NERVOUS SYSTEM DISORDER; NEUROLOGY; PROTEIN; RODENT;

ADENO ASSOCIATED VIRUS 9; ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN DYSFUNCTION; CEREBROSPINAL FLUID; CONTROLLED STUDY; FIBROBLAST; GLUCOSE BRAIN LEVEL; GLUCOSE TRANSPORT; GLUT1 DEFICIENCY SYNDROME; IN VITRO STUDY; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; THERAPEUTIC INDEX; ABNORMALITIES; ANIMAL; BRAIN; DEFICIENCY; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MALE; METABOLISM; MICROVASCULATURE; PATHOPHYSIOLOGY; VASCULARIZATION;

MUS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CARBOHYDRATE METABOLISM, INBORN ERRORS; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; MICE; MICROVESSELS; MONOSACCHARIDE TRANSPORT PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 85010046968     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14152     Document Type: Article

References (66)

1. Seidner, G. et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat. Genet. 18, 188-191 (1998).
2. De Vivo, D. C. et al. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N. Engl. J. Med. 325, 703-709 (1991).
3. Arsov, T. et al. Glucose transporter 1 deficiency in the idiopathic generalized epilepsies. Ann. Neurol. 72, 807-815 (2012).
4. Brockmann, K. The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev. 31, 545-552 (2009).
5. Veggiotti, P. & De Giorgis, V. Dietary treatments and new therapeutic perspective in GLUT1 deficiency syndrome. Curr. Treat. Options Neurol. 16, 291 (2014).
6. Wang, D. et al. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann. Neurol. 57, 111-118 (2005).
7. Vannucci, S. J. Developmental expression of GLUT1 and GLUT3 glucose transporters in rat brain. J. Neurochem. 62, 240-246 (1994).
8. Nordli, D. R. & De Vivo, D. C. The ketogenic diet revisited: back to the future. Epilepsia 38, 743-749 (1997).
9. Klepper, J. & Leiendecker, B. Glut1 deficiency syndrome and novel ketogenic diets. J. Child Neurol. 28, 1045-1048 (2013).
10. Pascual, J. M. & Ronen, G. M. Glucose transporter type 1 deficiency (G1D) at 25 (1990-2015): presumptions, facts, and the lives of persons with this rare disease. Pediatr. Neurol. 53, 379-393 (2015).
11. Wang, D. et al. A mouse model for Glut-1 haploinsufficiency. Hum. Mol. Genet. 15, 1169-1179 (2006).
12. Pascual, J. M., Van Heertum, R. L., Wang, D., Engelstad, K. & De Vivo, D. C. Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann. Neurol. 52, 458-464 (2002).
13. Pascual, J. M. et al. Brain glucose supply and the syndrome of infantile neuroglycopenia. Arch. Neurol. 64, 507-513 (2007).
14. Akman, C. I. et al. Topography of brain glucose hypometabolism and epileptic network in glucose transporter 1 deficiency. Epilepsy Res. 110, 206-215 (2015).
15. Moos, T. & Møllgard, K. Cerebrovascular permeability to azo dyes and plasma proteins in rodents of different ages. Neuropathol. Appl. Neurobiol. 19, 120-127 (1993).
16. Armulik, A. et al. Pericytes regulate the blood-brain barrier. Nature 468, 557-561 (2010).
17. Kirch, D. G. et al. Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia. J. Neural. Transm. Gen. Sect. 89, 219-232 (1992).
18. Eeg-Olofsson, O., Link, H. & Wigertz, A. Concentrations of CSF proteins as a measure of blood brain barrier function and synthesis of IgG within the CNS in 'normal' subjects from the age of 6 months to 30 years. Acta Paediatr. Scand. 70, 167-170 (1981).
19. Zucker, D. K., Wooten, G. F. & Lothman, E. W. Blood-brain barrier changes with kainic acid-induced limbic seizures. Exp. Neurol. 79, 422-433 (1983).
20. Saija, A. et al. Blood-brain barrier dysfunctions following systemic injection of kainic acid in the rat. Life Sci. 51, 467-477 (1992).
21. Knowland, D. et al. Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. Neuron 82, 603-617 (2010).
22. Macdonald, J. A., Murugesan, N. & Pachter, J. S. Endothelial cell heterogeneity of blood-brain barrier gene expression along the cerebral microvasculature. J. Neurosci. Res. 88, 1457-1474 (2010).
23. Nitta, T. et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 161, 653-660 (2003).
24. Durmus, S. et al. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Pharmacol. Res. 76, 9-16 (2013).
25. Gavard, J. Endothelial permeability and VE-cadherin: a wacky comradeship. Cell Adh. Migr. 8, 158-164 (2014).
26. Shue, E. H. et al. Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neurosci. 9, 29 (2014).
27. Liebner, S. et al. Wnt/beta-catenin signaling controls development of the bloodbrain barrier. J. Cell Biol. 183, 409-417 (2014).
28. Wolburg, H. et al. Localization of claudin-3 in tight junctions of the bloodbrain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol. 105, 586-592 (2003).
29. Biou, D. et al. Cerebrospinal fluid protein concentrations in children: agerelated values in patients without disorders of the central nervous system. Clin. Chem. 46, 399-403 (2000).
30. Shibuya, M. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 13, 63-69 (2006).
31. Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66 (1995).
32. Vandekeere, S., Dewerchin, M. & Carmeliet, P. Angiogenesis revisited: an overlooked role of endothelial cell metabolism in vessel sprouting. Microcirculation 22, 509-517 (2015).
33. De Bock, K. et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154, 651-663 (2013).
34. Qian, W. & Van Houten, B. Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods 51, 452-457 (2010).
35. Gao, G. et al. Novel adeno-Associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl Acad. Sci. USA 99, 11854-11859 (2002).
36. Gao, G. et al. Clades of Adeno-Associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388 (2004).
37. Gao, G., Vandenberghe, L. H. & Wilson, J. M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285-297 (2005).
38. Vandenberghe, L. H., Wilson, J. M. & Gao, G. Tailoring the AAV vector capsid for gene therapy. Gene Ther. 16, 311-319 (2009).
39. Foust, K. D. et al. Rescue of the spinal muscular atrophy phenotype in a mouse model of early postnatal delivery of SMN. Nat. Biotechnol. 28, 271-274 (2010).
40. Yang, H. et al. Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann. Neurol. 70, 996-1005 (2011).
41. Ullner, P. M. et al. Murine Glut-1 transporter haploinsufficiency: postnatal deceleration of brain weight and reactive astrocytosis. Neurobiol. Dis. 36, 60-69 (2009).
42. McCaslin, A. F. et al. In vivo 3D morphology of astrocyte-vasculature interactions in the somato-sensory cortex: implications for neurovascular coupling. J. Cereb. Blood Flow Metab. 31, 795-806 (2011).
43. Görs, S., Kucia, M., Langhammer, M., Junghans, P. & Metges, C. C. Technical note: milk composition in mice--methodological aspects and effects of mouse strain and lactation day. J. Dairy Sci. 92, 632-637 (2009).
44. Butchbach, M. E., Singh, J., Gurney, M. E. & Burghes, A. H. The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice. Exp. Neurol. 256, 1-6 (2014).
45. Pellerin, L., Pellegri, G., Martin, J. L. & Magistretti, P. J. Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain. Proc. Natl Acad. Sci. USA 95, 3990-3995 (1998).
46. Vannucci, S. J. & Simpson, I. A. Developmental switch in brain nutrient transporter expression in the rat. Am. J. Physiol. Endocrinol. Metab. 285, E1127-E1134 (2003).
47. Simpson, I. A., Vannucci, S. J. & Maher, F. Glucose transporters in mammalian brain. Biochem. Soc. Trans. 22, 671-675 (1994).
48. Mancuso, M. R., Kuhnert, F. & Kuo, C. J. Developmental angiogenesis of the central nervous system. Lymphat. Res. Biol. 6, 173-180 (2008).
49. Zheng, P. P. et al. Glut1/SLC2A1 is crucial for the development of the bloodbrain barrier in vivo. Ann. Neurol. 68, 835-844 (2010).
50. Winkler, E. A. et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat. Neurosci. 18, 521-530 (2015).
51. Esraghi, M., McFall, E., Gibeault, S. & Kothary, R. Effect of genetic background on the phenotype of the Smn2B/ mouse model of spinal muscular atrophy. Hum. Mol. Genet, doi: 10.1093/hmg/ddw278 (2016).
52. Schauwecker, P. E. The relevance of individual genetic background and its role in animal models of epilepsy. Epilepsy Res. 97, 1-11 (2011).
53. Tung, J. J., Tattersall, I. W. & Kitajewski, J. Tips, stalks, tubes: notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis. Cold Spring Harb. Perspect. Med. 2, a006601 (2012).
54. Harb, R., Whiteus, C., Freitas, C. & Grutzendler, J. In vivo imaging of cerebral microvascular plasticity from birth to death. J. Cereb. Blood Flow Metab. 33, 146-156 (2013).
55. Xu, Y. et al. Endothelial PFKFB3 plays a critical role in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 34, 1231-1239 (2014).
56. Kariya, S. et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 2552-2569 (2008).
57. Kariya, S. et al. Requirement of enhanced survival motoneuron protein imposed during neuromuscular junction maturation. J. Clin. Invest. 124, 785-800 (2014).
58. Matsuura, K., Kabuto, H., Makino, H. & Ogawa, N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 73, 45-48 (1997).
59. Gao, G. P. & Sena-Esteves, M. in Molecular Cloning, Vol 2: A Laboratory Manual. (eds Green, M. R. & Sambrook, J.) 1209-1313 (Cold Spring Harbor Laboratory Press, New York, 2012).
60. Yardeni, T., Eckhaus, M., Morris, H. D., Huizing, M. & Hoogstraten-Miller, S. Retro-orbital injections in mice. Lab Anim. 40, 155-160 (2011).
61. Glascock, J. J. et al. Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice. J. Vis. Exp. 56, 2968 (2011).
62. Monani, U. R. et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333-339 2000
63. Galwaduge, P. T., Kim, S. H., Grosberg, L. E. & Hillman, E. M. Simple wavefront correction framework for two-photon microscopy of in-vivo brain. Biomed. Opt. Express 6, 2997-3013 (2015).
64. Cebulla, J., Kim, E., Rhie, K., Zhang, J. & Pathak, A. P. Multiscale and multimodality visualization of angiogenesis in a human breast cancer model. Angiogenesis 17, 695-709 (2014).
65. Pons, R., Collins, A., Rotstein, M., Engelstad, K. & De Vivo, D. C. The spectrum of movement disorders in Glut-1 deficiency. Mov. Disord. 25, 275-281 2010
66. Llorente-Folch, I., Rueda, C. B., Pérez-Liébana, I., Satrústegui, J. & Pardo, B. L-lactate-mediated neuroprotection against glutamate-induced excitotoxicity requires ARALAR/AGC1. J. Neurosci. 36, 4443-4456 (2016).